News | Radiation Therapy | May 12, 2016

Prolonged Breath Holds Could Help in Targeted Breast Cancer Radiotherapy

U.K. study demonstrates patients can be trained to achieve single prolonged breath-holds of more than five minutes to deliver radiation dose in a single breath-hold

breast cancer, radiation therapy, extended breath-hold, University of Birmingham study

May 12, 2016 — Researchers in the United Kingdom have successfully shown for the first time that breast cancer patients can be trained to achieve single prolonged breath-holds of over five minutes. These findings open the door for targeted radiotherapy to be administered with just one dose in each daily session.

A typical radiotherapy beam in each daily session takes two minutes to deliver, with shaped radiation beams directed from several angles to intersect at the cancerous tumor. Because patients are not able to hold their breath for this long, most radiotherapy treatment is delivered while still breathing, and the ventilatory motion of the chest increases the risk of damage to nearby healthy tissue.

Clinical practice for some breast cancer patients is due to change with the introduction of repeated breath-holds of around 20 seconds, to provide a stable target for the treatment, given over a number of doses in each session.

But the Birmingham team have demonstrated that the treatment in each session could now be delivered to patients in a single breath-hold.

The research “Safely prolonging single breath-holds to >5 minutes in cancer patients; feasibility and applications for radiotherapy“ published in the British Journal of Radiology, builds on previous studies of healthy volunteers who were able to reach mean breath holds of seven minutes.

Dr. Mike Parkes, from the University of Birmingham, explained, “The physiology of breath holding is well understood on the whole, but has been somewhat overlooked in medical research because until now it hadn’t any obvious clinical application.”

“Following on from our preliminary work on healthy subjects, we wanted to see if we could help patients with breast cancer to achieve a breath hold of over two minutes to allow a radiotherapy treatment to be delivered in a single breath-hold.”

Fifteen patients who were undergoing radiotherapy were recruited to the trial and trained to extend their breath-holds safely. Patients are trained on how to maintain a relaxed posture, to practice inhaling and exhaling to maximum effect and then to assist them naturally to raise their blood oxygen levels and reduce their blood carbon dioxide levels, by preoxygenation and mechanically induced hypocapnia.

The average breath hold of patients after the training was 5.3 minutes, significantly more than the required target of 2 minutes.

Parkes continued, “Being able to hit the cancerous tumor accurately is essential to avoid damage to other areas, including the heart muscle. Having a stable chest that we can target in one dose could be invaluable in protecting the surrounding tissue.”

“Although 5-minute breath-holds may seem astonishing to people, it is perfectly natural and safe for patients. Actually, anyone can do it. Patients are carefully monitored throughout the process and if their oxygen levels drop or their blood pressure rises above a certain level we would step in. The safety levels we use are very conservative so there is no risk attached.”

Of all 15 patients undergoing radiotherapy, 13 also had chemotherapy and two were taking herceptin.

The Birmingham team, working with clinical teams at University Hospitals Birmingham NHS Foundation Trust, believe that being able to assist patients in achieving a single breath-hold could greatly improve the long-term survival and quality of life of breast cancer patients.

The trial was funded by the Queen Elizabeth Hospital Birmingham Charity as part of the Charity’s ongoing multi-million pound support of patients at the hospital.

For more information: www.birpublications.org/journal/bjr

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...